Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children
Hyeon-Jong Yang (Yang HJ)
Clin Exp Pediatr. 2019;62(6):199-205.   Published online 2019 Mar 15     DOI: https://doi.org/10.3345/kjp.2018.07367
Citations to this article as recorded by Crossref logo
Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children
Ti-An Tsai, Chang-Ku Tsai, Kuang-Che Kuo, Hong-Ren Yu
Journal of Microbiology, Immunology and Infection.2021; 54(4): 557.     CrossRef
Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan
Chih-Hao Chang, Chang-Ku Tsai, Ti-An Tsai, Sui-Ching Wang, Yi-Chen Lee, Chih-Min Tsai, Ta-Yu Liu, Kuang-Che Kuo, Chih-Cheng Chen, Hong-Ren Yu
Pediatrics & Neonatology.2021; 62(5): 536.     CrossRef
Are alternative antibiotics needed for antibiotic-nonresponsive Mycoplasma pneumoniae pneumonia?
Eun-Ae Yang, Kyung-Yil Lee
Clinical and Experimental Pediatrics.2020; 63(2): 44.     CrossRef
How can we treat childhood mycoplasma pneumonia in real practice?
Hyeon-Jong Yang
Allergy, Asthma & Respiratory Disease.2020; 8(2): 51.     CrossRef
Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone
Xin Yuan, Jie Liu, Changqing Bai, Wenkai Niu, Jingjing Wang, Puyuan Li, Huiying Liu, Yuan Luo
Medicine.2020; 99(28): e21128.     CrossRef
Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia
Abdul-Rahman Mamdouh Mohammad, Rehab Mahmoud Abd El-Baky, Eman Farouk Ahmed
Journal of Pure and Applied Microbiology.2020; 14(4): 2265.     CrossRef